-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In a new study, researchers from the La Jolla Institute of Immunology (LJI) in the United States helped answer a question: How long can the vaccinated person's immunity to COVID-19 last? They report that the immunity produced by the low-dose Moderna mRNA-1273 new crown vaccine can last at least six months, and there is no sign that vaccinators need booster injections
.
The relevant research results were published online in the journal Science on September 14, 2021.
The title of the paper is "Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells"
.
Dr.
Daniela Weiskopf, the co-corresponding author of the paper and LJI research assistant professor, said, "This time point is very important, because at this time the real immune memory has been formed
.
" The other two co-corresponding authors of the paper are Professor Alessandro Sette and Professor Shane Crotty of LJI
.
In fact, although the Moderna mRNA-1273 new crown vaccine caused a strong CD4+ (helper) T cell, CD8+ (killer) T cell and antibody response at least 6 months after the clinical trial participants were fully vaccinated, this immunity The reaction is likely to last longer
.
The authors also found that this strong immune memory persisted in all age groups tested, including people over 70 years old, a population that is particularly vulnerable to severe COVID-19
.
Crotty added, “Immune memory is very stable, which is impressive
.
This is a good indicator of the durability of mRNA vaccines
.
” Comparing Moderna vaccine with natural immunity.
These authors compared recovered COVID-19 patients with Trial participants who received a dose of 25 micrograms of Moderna's new crown vaccine during the phase 1 clinical trial were compared
.
The first author of the paper and LJI postdoctoral researcher Jose Mateus Triviño said, “We want to see if a quarter of the dose can induce any immune response
.
We have the opportunity to receive samples from the original Moderna/NIH Phase 1 trial participants.
They received two injections of 25 micrograms of Moderna vaccine, 28 days apart
.
"This vaccine dose is one-fourth of the 100 micrograms of Moderna's new crown vaccine authorized by the U.
S.
Food and Drug Administration (FDA)
.
Although these authors do not know whether this smaller dose is as effective as the standard dose, this new study shows that the T cell and antibody response in the smaller dose group is still strong
.
Transmission electron microscope images of SARS-CoV-2, a novel coronavirus infection (coronavirus that causes COVID-19) isolated from American patients, showed that virus particles appeared on the surface of cells cultured in the laboratory
.
The name of the coronavirus is derived from the crown spikes on the outer edge of the virus particle
.
The picture comes from NIAID-RML
.
In fact, these authors found that Moderna's new crown vaccine stimulated an adaptive immune response to the SARS-CoV-2 spike protein (a key target), almost the same as the immune system's response to SARS-CoV-2 natural infection
.
Weiskopf said, "This immune response is comparable
.
It is neither high nor low
.
" This new study does not show that the lower dose of Moderna's new crown vaccine provides the same protection as the standard dose
.
Crotty said, "This will require a clinical trial to tell how low-dose protection is
.
" The common cold coronavirus does prepare the immune system.
This new study also shows the power of "cross-reactive" T cells.
.
In a 2020 study published in the journal Science, the LJI team showed that the T cells of people who have recovered from the common cold coronavirus can respond to the new coronavirus SARS-CoV-2 (Science, 2020, doi: 10.
1126/science.
abd3871)
.
At the time, they didn't know whether this cross-reactivity could really protect people from COVID-19
.
Sette said, "It is important to understand the role of cross-reactive T cells because T cells play an important role in controlling and resolving COVID-19 infection
.
" For this new study, these authors found that there are cross-reactive T cells.
Of people have significantly stronger CD4+ T cell and antibody responses to both doses of Moderna's new crown vaccine
.
Sette said, "If you have this kind of immune reactivity, your immune system may start to fight the virus faster
.
There have been multiple studies showing that the immune system's response speed is the key
.
"Moderna's new crown vaccine activates "killer" T cells.
The team has also filled an important gap in COVID-19 vaccine research
.
So far, many studies have shown an effective CD4+ T cell response to Moderna's new crown vaccine, but CD8 + T cell response data is lacking
.
Mateus Triviño said, “We know that people who are naturally infected and recovered have a good CD8+ T cell response to SARS-CoV-2; however, people are The cell is worried
.
"Sette said that this new study shows a strong CD8+ T cell response to the low-dose Moderna Covid-19 vaccine, similar to the response of patients to natural SARS-CoV-2 infection
.
Weiskopf added, "We see a strong CD8+T cell response --- We have used a variety of detection methods to prove this
.
"Next, Weiskopf and her colleagues are investigating whether this vaccine persistence is also applicable to other types of COVID-19 vaccines? At the same time, Weiskopf said that real-world data shows that immune memory can indeed be sustained
.
They also Interested in the durability of Moderna's new crown vaccine compared with other COVID-19 vaccines in use
.
Reference: Jose Mateus et al.
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells.
Science , 2021, doi:10.
1126/science.
abj9853.
.
The relevant research results were published online in the journal Science on September 14, 2021.
The title of the paper is "Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells"
.
Dr.
Daniela Weiskopf, the co-corresponding author of the paper and LJI research assistant professor, said, "This time point is very important, because at this time the real immune memory has been formed
.
" The other two co-corresponding authors of the paper are Professor Alessandro Sette and Professor Shane Crotty of LJI
.
In fact, although the Moderna mRNA-1273 new crown vaccine caused a strong CD4+ (helper) T cell, CD8+ (killer) T cell and antibody response at least 6 months after the clinical trial participants were fully vaccinated, this immunity The reaction is likely to last longer
.
The authors also found that this strong immune memory persisted in all age groups tested, including people over 70 years old, a population that is particularly vulnerable to severe COVID-19
.
Crotty added, “Immune memory is very stable, which is impressive
.
This is a good indicator of the durability of mRNA vaccines
.
” Comparing Moderna vaccine with natural immunity.
These authors compared recovered COVID-19 patients with Trial participants who received a dose of 25 micrograms of Moderna's new crown vaccine during the phase 1 clinical trial were compared
.
The first author of the paper and LJI postdoctoral researcher Jose Mateus Triviño said, “We want to see if a quarter of the dose can induce any immune response
.
We have the opportunity to receive samples from the original Moderna/NIH Phase 1 trial participants.
They received two injections of 25 micrograms of Moderna vaccine, 28 days apart
.
"This vaccine dose is one-fourth of the 100 micrograms of Moderna's new crown vaccine authorized by the U.
S.
Food and Drug Administration (FDA)
.
Although these authors do not know whether this smaller dose is as effective as the standard dose, this new study shows that the T cell and antibody response in the smaller dose group is still strong
.
Transmission electron microscope images of SARS-CoV-2, a novel coronavirus infection (coronavirus that causes COVID-19) isolated from American patients, showed that virus particles appeared on the surface of cells cultured in the laboratory
.
The name of the coronavirus is derived from the crown spikes on the outer edge of the virus particle
.
The picture comes from NIAID-RML
.
In fact, these authors found that Moderna's new crown vaccine stimulated an adaptive immune response to the SARS-CoV-2 spike protein (a key target), almost the same as the immune system's response to SARS-CoV-2 natural infection
.
Weiskopf said, "This immune response is comparable
.
It is neither high nor low
.
" This new study does not show that the lower dose of Moderna's new crown vaccine provides the same protection as the standard dose
.
Crotty said, "This will require a clinical trial to tell how low-dose protection is
.
" The common cold coronavirus does prepare the immune system.
This new study also shows the power of "cross-reactive" T cells.
.
In a 2020 study published in the journal Science, the LJI team showed that the T cells of people who have recovered from the common cold coronavirus can respond to the new coronavirus SARS-CoV-2 (Science, 2020, doi: 10.
1126/science.
abd3871)
.
At the time, they didn't know whether this cross-reactivity could really protect people from COVID-19
.
Sette said, "It is important to understand the role of cross-reactive T cells because T cells play an important role in controlling and resolving COVID-19 infection
.
" For this new study, these authors found that there are cross-reactive T cells.
Of people have significantly stronger CD4+ T cell and antibody responses to both doses of Moderna's new crown vaccine
.
Sette said, "If you have this kind of immune reactivity, your immune system may start to fight the virus faster
.
There have been multiple studies showing that the immune system's response speed is the key
.
"Moderna's new crown vaccine activates "killer" T cells.
The team has also filled an important gap in COVID-19 vaccine research
.
So far, many studies have shown an effective CD4+ T cell response to Moderna's new crown vaccine, but CD8 + T cell response data is lacking
.
Mateus Triviño said, “We know that people who are naturally infected and recovered have a good CD8+ T cell response to SARS-CoV-2; however, people are The cell is worried
.
"Sette said that this new study shows a strong CD8+ T cell response to the low-dose Moderna Covid-19 vaccine, similar to the response of patients to natural SARS-CoV-2 infection
.
Weiskopf added, "We see a strong CD8+T cell response --- We have used a variety of detection methods to prove this
.
"Next, Weiskopf and her colleagues are investigating whether this vaccine persistence is also applicable to other types of COVID-19 vaccines? At the same time, Weiskopf said that real-world data shows that immune memory can indeed be sustained
.
They also Interested in the durability of Moderna's new crown vaccine compared with other COVID-19 vaccines in use
.
Reference: Jose Mateus et al.
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells.
Science , 2021, doi:10.
1126/science.
abj9853.
